MeSH D011655 - pulmonary embolism
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D004617:Embolism
$
Success rate
D008171:Lung diseases
$
Success rate
D011655: 
Pulmonary embolism
D054060:Pulmonary infarction
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Taro PharmaceuticalWarfarin Warfarin  1999-07-15   
LEO PharmaTinzaparin Innohep  2000-07-14   
MylanApixaban Apixaban  2019-12-23   
Fondaparinux Arixtra  2001-12-07   
Heparin Heparin  2017-11-30   
Rivaroxaban Rivaroxaban Viatris (previously Rivaroxaban Mylan)  2021-11-12   
Dabigatran etexilate Dabigatran Etexilate  2025-02-03   
Johnson & JohnsonRivaroxaban Xarelto 2024-08-28 2011-07-01 $2,373 M Y2024 
GSKFondaparinux Quixidar  2002-03-21   
CiplaWarfarin Warfarin  2011-05-25   
SandozEnoxaparin Enoxaparin  2010-07-23   
Heparin Heparin  2011-06-08   
Boehringer IngelheimDabigatran etexilate Pradaxa 2023-06-14 2010-10-19   
Aspen GlobalHeparin Liquaemin  1982-01-01   
OrganonPhenprocoumon Liquamar  1982-01-01   
1
2
3
4
5
6
...
8
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use